Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astellas Pharma Inc
(OP:
ALPMY
)
9.500
+0.030 (+0.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astellas Pharma Inc
< Previous
1
2
3
Next >
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
January 24, 2023
Via
Benzinga
What Is Going on With Taysha Gene (TSHA) Stock Today?
October 25, 2022
Taysha and its new partner Astellas are both speculating that Adeno Associated Viruses can create treatments for genetic diseases.
Via
InvestorPlace
Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs
October 25, 2022
Via
Benzinga
Astellas' Menopause Drug Under FDA Review
August 18, 2022
Via
Benzinga
Seagen Shares Jump On Positive Data From Urothelial Cancer Trial
July 26, 2022
Via
Benzinga
7 Best Biotech Stocks to Buy in July 2022
July 08, 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.
Via
InvestorPlace
Sutro Biopharma Stock Surges On Cancer Treatment Pact
June 28, 2022
Via
Benzinga
Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold
June 27, 2022
Via
Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
June 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies
May 09, 2022
Via
Benzinga
Astellas - Seagen's Padcev Approved In Europe For Most Common Form Of Bladder Cancer
April 13, 2022
The
Via
Benzinga
Astellas' Menopause Drug Suffers Setback After Failed Asian Trial
March 15, 2022
Via
Benzinga
Astellas Touts Safety Data For Phase 3 Menopause Drug, Sets Up US Filing
March 07, 2022
Astellas Pharma Inc (OTC: ALPMF) announced topline results from the Phase 3 SKYLIGHT 4 trial investigating the long-term safety of fezolinetant in vasomotor...
Via
Benzinga
Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients
February 15, 2022
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced the initial results from Cohort H of the EV-103 trial investigating PADCEV (...
Via
Benzinga
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
December 02, 2021
Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS) and Roche Holdings AG (OTC: RHHBY...
Via
Benzinga
4 No-Brainer Pharmaceutical Stocks to Buy in October
September 27, 2021
While the resurgence of COVID-19 cases is driving the demand for vaccines, booster shots, and other related solutions, an aging population is expected to be a key growth driver for the pharmaceutical...
Via
Talk Markets
Exposures
COVID-19
Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan
September 27, 2021
Japan's Ministry of Health, Labor, and Welfare (MHLW) has approved Astellas Pharma Inc's (OTC: ALPMF) Padcev (enfortumab vedotin) for radically...
Via
Benzinga
Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold
September 14, 2021
Astellas Pharma Inc (OTC: ALPMF) has seen the fourth death in its experimental gene therapy trial gained through a $3 billion buyout of Audentes Therapeutics...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
September 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE...
Via
Benzinga
Exposures
COVID-19
See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial
September 01, 2021
Astellas Pharma Inc (OTC: ALPMF) has voluntarily paused screening and dosing of additional participants in its ASPIRO trial evaluating AT132 gene therapy in...
Via
Benzinga
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
August 20, 2021
The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
September 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU...
Via
Benzinga
Here's What Recent News From the FDA Means for AstraZeneca
August 20, 2021
Even though AstraZeneca and FibroGen must now conduct an additional safety trial to have a chance at FDA approval, not all is lost.
Via
The Motley Fool
Exposures
Product Safety
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
August 11, 2021
The FDA has issued a complete response letter regarding the marketing application for FibroGen Inc's (NASDAQ: FGEN) roxadustat for anemia of chronic kidney disease...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
August 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...
Via
Benzinga
Exposures
COVID-19
The IPO Recap – Party Is Everything But Over
July 28, 2021
Last week's 19 IPO week had a lot of life sciences and software. This week, US IPO activity continues at a record with 25 scheduled IPOs, marking the fifth week in 2021 with...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer
July 12, 2021
The FDA granted full approval and a label expansion for Seagen Inc (NASDAQ: SGEN) - Astellas Pharma Inc's (OTC: ALPMF) PADCEV to treat...
Via
Benzinga
Exposures
Product Safety
The 2 Best Pharma Stocks to Buy on Dips
June 23, 2021
Because the COVID-19 pandemic is under control in most major economies, the hype surrounding vaccine producers is gradually tapering off.
Via
Talk Markets
Exposures
COVID-19
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows
May 11, 2021
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-...
Via
Benzinga
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics
May 03, 2021
Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.